Compounds > isolongifolol
Page last updated: 2024-11-12

isolongifolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isolongifolol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12311096
CHEMBL ID388140
MeSH IDM0487447

Synonyms (7)

Synonym
CHEMBL388140 ,
isolongifolol
((1s,3ar,4s,8ar,9s)-4,8,8-trimethyl-decahydro-1,4-methano-azulen-9-yl)-methanol
bdbm50211775
[(1r,2s,7s,8s,9s)-3,3,7-trimethyl-8-tricyclo[5.4.0.02,9]undecanyl]methanol
[(1r,2s,7s,8r,9r)-3,3,7-trimethyl-8-tricyclo[5.4.0.02,9]undecanyl]methanol
1,4-methanoazulene-9-methanol, decahydro-4,8,8-trimethyl-, (1s,3ar,4s,8as,9s)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 2B7Homo sapiens (human)IC50 (µMol)0.10000.10002.50004.9000AID288412
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID288410Inhibition of human UGT2B7 assessed as reduction of estriol glucuronidation at 1 uM2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.
AID288408Inhibition of human UGT2B7 assessed as reduction of estriol glucuronidation at 100 uM2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.
AID288409Inhibition of human UGT2B7 assessed as reduction of estriol glucuronidation at 10 uM2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.
AID288412Inhibition of human UGT2B7 assessed as reduction of estriol glucuronidation2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.
AID288411Inhibition of human UGT2B7 assessed as reduction of estriol glucuronidation at 0.1 uM2007Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.80 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ledol
ledol: from Renealmia chrysotrycha; structure in first source		2.0710
sesquiterpenes
[no description available]		3.1450
caryophyllene
caryophyllene: RN given refers to cpd without isomeric designation; structure given in first source		2.0710
bisabolol
bisabolol: monocyclic sesquiterpene alcohol with strong bacteriocidal effects, especilly against M. Tuberc.; isolated from seed plant Populus tacamacaha; RN given refers to cpd without isomeric desigation		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials